What question did this study set out to answer?

The study aims to analyze clinical outcomes and biological factors in patients with metastatic uterine sarcomas.

August 1, 2026CureusOpen Access

Metastatic Uterine Sarcomas: A Retrospective Analysis on Clinical Outcomes and Biology

View Full Paper

Ask AI

Bookmark

The study aims to analyze clinical outcomes and biological factors in patients with metastatic uterine sarcomas.
Retrospective analysis of patients treated between January 2018 and December 2025.
Inclusion of patients with unresectable or metastatic uterine sarcomas treated with palliative intent.
Data collected on treatment regimens and survival rates.
Disease control rate (DCR) was 56.52% among those receiving treatment.
Overall survival (OS) for the cohort was five months, with variations by histologic subtype.
Patients with tumors ≤10 cm had a median OS of 10 months compared to 5 months for tumors >10 cm (p=0.031).

No takes yet. Share an insight, caveat, or question.

Retrospective analysis reports outcomes in patients with metastatic uterine sarcomas, highlighting poor prognosis.

Singh et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark